[Hu B, et al. Signal Transduct Target Ther. 2020;1a;2a;8b] Inclisiran (Leqvio, Novartis) is an siRNA that specifically targets the human PCSK9 mRNA. Inclisiran first received FDA approval in 2021.

Inclisiran is one of a number of new therapies called small interfering RNA (siRNA) drugs. These treatments essentially modify the genetic code inside cells, changing how the body functions.

GalNAc is a widely used delivery method for siRNA therapies ... and Novartis’s Leqvio (inclisiran). Under the third agreement ...

The first-in-class, small interfering RNA (siRNA) therapy for cholesterol lowering ... for Regeneron in the same period. Novartis added inclisiran to its pipeline after buying The Medicines ...

Second, we demonstrated the broad potential utility of our ECO Synthesis platform by successfully synthesizing inclisiran, a commercially approved siRNA drug, by four different methods ranging ...

Reporting in Nature, Kumar and colleagues have now developed a method to target small-interfering RNA (siRNA) to the CNS, providing a safe and non-invasive approach for the delivery of this new ...

The double-stranded RNA is processed by an RNase III family enzyme Dicer, resulting in the generation of an siRNA, a 21–23-nucleotide (nt) RNA duplex, composed of a 19-mer sequence with ...

Novartis and NHS England have forged a pact to accelerate the access of its new cholesterol-lowering drug inclisiran for primary prevention of cardiovascular disease. Health Secretary Matt Hancock ...

Second, we demonstrated the broad potential utility of our ECO Synthesis platform by successfully synthesizing inclisiran, a commercially approved siRNA drug, by four different methods ranging ...